TALDO1 promotes lipid metabolic reprogramming and immunosuppressive microenvironment remodelling in hepatocellular carcinoma

Abstract

Background: Hepatocellular carcinoma (HCC) is characterized by pronounced metabolic reprogramming and is frequently accompanied by the development of an immunosuppressive microenvironment. However, the key molecular mediators linking tumour metabolic dysregulation to immune microenvironment remodelling remain insufficiently defined. This study aimed to identify critical metabolic genes in HCC and to investigate their roles in lipid metabolic reprogramming and immunosuppression.

Methods: A deep autoencoder was used to extract latent metabolic features from HCC and identify TALDO1 as a key candidate gene. The expression pattern and prognostic significance of TALDO1 were evaluated across multiple independent cohorts and further validated in clinical specimens. Multi-omics analyses combined with experimental validation were then used to elucidate the role of TALDO1 in lipid metabolic reprogramming and its effects on immune microenvironment remodelling in HCC.

Results: TALDO1 was identified as a key metabolic gene associated with HCC progression and was consistently upregulated across multiple clinical cohorts. Mechanistically, TALDO1 promoted lipogenesis and lipid accumulation in HCC cells by suppressing AMPK activation and sustaining SREBP1 maturation. TALDO1 silencing also reduced the secretion of several fatty acids and lipid mediators. Multi-omics analyses together with multiplex immunofluorescence validation showed that high TALDO1 expression was associated with an immunosuppressive microenvironment in HCC. Coculture experiments further demonstrated that TALDO1 silencing attenuated the ability of HCC cells to induce M2-like macrophage polarization and promote phenotypes associated with T-cell exhaustion. In vivo, TALDO1 loss was accompanied by reduced immunosuppressive cell infiltration, enhanced effector T-cell activity, and impaired tumour growth. Consistently, TALDO1 silencing also markedly suppressed tumour growth in patient-derived xenograft models.

Conclusions: TALDO1 promotes lipid metabolic reprogramming in HCC and participates in the formation of an immunosuppressive microenvironment. These findings suggest that TALDO1 may serve as a key molecule linking metabolic abnormalities to immune microenvironment remodelling and may have potential therapeutic significance.

Keywords

hepatocellular carcinoma / immunosuppression / lipid metabolic reprogramming / multi-omics / single-cell RNA sequencing / tumour microenvironment

References

[1] Zhang C-H, Cheng Y, Zhang S, Fan J, Gao Q. Changing epidemiology of hepatocellular carcinoma in Asia. Liver Int. 2022; 42(9): 2029–2041.

[2] Mcglynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology. 2021; 73(1): 4–13.

[3] Fu Y, Maccioni L, Wang XW, Greten TF, Gao B. Alcohol-associated liver cancer. Hepatology. 2024; 80(6): 1462–1479.

[4] Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022; 77(6): 1598–1606.

[5] Toh MR, Wong EYT, Wong SH, et al. Global epidemiology and genetics of hepatocellular carcinoma. Gastroenterology. 2023; 164(5): 766–782.

[6] Sies H, Mailloux RJ, Jakob U. Fundamentals of redox regulation in biology. Nat Rev Mol Cell Biol. 2024; 25(9): 701–719.

[7] Faubert B, Solmonson A, DeBerardinis RJ. Metabolic reprogramming and cancer progression. Science. 2020(6487): 368:eaaw5473.

[8] Park S, Hall MN. Metabolic reprogramming in hepatocellular carcinoma: mechanisms and therapeutic implications. Exp Mol Med. 2025; 57(3): 515–523.

[9] Yang F, Hilakivi-Clarke L, Shaha A, et al. Metabolic reprogramming and its clinical implication for liver cancer. Hepatology. 2023; 78(5): 1602–1624.

[10] Cassim S, Raymond V-A, Dehbidi-Assadzadeh L, Lapierre P, Bilodeau M. Metabolic reprogramming enables hepatocarcinoma cells to efficiently adapt and survive to a nutrient-restricted microenvironment. Cell Cycle. 2018; 17(7): 903–916.

[11] Khalaf K, Hana D, Chou JT-T, Singh C, Mackiewicz A, Kaczmarek M. Aspects of the tumor microenvironment involved in immune resistance and drug resistance. Front Immunol. 2021; 12:656364.

[12] Saravia J, Chi H. Immunometabolism of regulatory T cells in cancer. Oncogene. 2025; 44(25): 2011–2024.

[13] Yan Y, Huang L, Liu Y, et al. Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity. J Hematol Oncol. 2022; 15(1): 104.

[14] Kondo M, Kumagai S, Nishikawa H. Metabolic advantages of regulatory T cells dictated by cancer cells. Int Immunol. 2024; 36(2): 75–86.

[15] Li M, Yang Y, Xiong L, Jiang P, Wang J, Li C. Metabolism, metabolites, and macrophages in cancer. J Hematol Oncol. 2023; 16(1): 80.

[16] Doncevic D, Herrmann C. Biologically informed variational autoencoders allow predictive modeling of genetic and drug-induced perturbations. Bioinformatics. 2023; 39(6):btad387.

[17] Stincone A, Prigione A, Cramer T, et al. The return of metabolism: biochemistry and physiology of the pentose phosphate pathway. Biol Rev. 2015; 90(3): 927–963.

[18] Qian Y, Banerjee S, Grossman CE, et al. Transaldolase deficiency influences the pentose phosphate pathway, mitochondrial homoeostasis and apoptosis signal processing. Biochem J. 2008; 415(1): 123–134.

[19] Jiang P, Du W, Wu M. Regulation of the pentose phosphate pathway in cancer. Protein & Cell. 2014; 5(8): 592–602.

[20] Ding Y, Gong C, Huang D, et al. Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers. Nat Commun. 2018; 9(1): 4274.

[21] Cen K, Lu C. Prognostic and immune infiltration analysis of Transaldolase 1 (TALDO1) in hepatocellular carcinoma. Int J Gen Med. 2023; 16: 5779–5788.

[22] Shi X, Zhao Y, Li K, et al. Plasma proteomic signature for preoperative prediction of microvascular invasion in HCC. JHEP Reports. 2025; 7(9):101481.

[23] Herzig S, Shaw RJ. AMPK: guardian of metabolism and mitochondrial homeostasis. Nat Rev Mol Cell Biol. 2018; 19(2): 121–135.

[24] Arner EN, Rathmell JC. Metabolic programming and immune suppression in the tumor microenvironment. Cancer Cell. 2023; 41(3): 421–433.

[25] Lin J, Rao D, Zhang M, Gao Q. Metabolic reprogramming in the tumor microenvironment of liver cancer. J Hematol Oncol. 2024; 17(1): 6.

[26] Xu F-Q, Dong M-M, Wang Z-F, Cao L-D. Metabolic rearrangements and intratumoral heterogeneity for immune response in hepatocellular carcinoma. Front Immunol. 2023; 14:1083069.

[27] Perl A, Hanczko R, Telarico T, Oaks Z, Landas S. Oxidative stress, inflammation and carcinogenesis are controlled through the pentose phosphate pathway by transaldolase. Trends Mol Med. 2011; 17(7): 395–403.

[28] Moriyama T, Tanaka S, Nakayama Y, et al. Two isoforms of TALDO1 generated by alternative translational initiation show differential nucleocytoplasmic distribution to regulate the global metabolic network. Sci Rep. 2016; 6:34648.

[29] Hanczko R, Fernandez DR, Doherty E, et al. Prevention of hepatocarcinogenesis and increased susceptibility to acetaminophen-induced liver failure in transaldolase-deficient mice by N-acetylcysteine. J Clin Invest. 2009; 119(6): 1546–1557.

[30] Perl A, Qian Y, Chohan KR, et al. Transaldolase is essential for maintenance of the mitochondrial transmembrane potential and fertility of spermatozoa. Proc Natl Acad Sci. 2006; 103(40): 14813–14818.

[31] Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol. 2012; 13(4): 251–262.

[32] Auciello FR, Ross FA, Ikematsu N, Hardie DG. Oxidative stress activates AMPK in cultured cells primarily by increasing cellular AMP and/or ADP. FEBS Lett. 2014; 588(18): 3361–3366.

[33] Lyssiotis CA, Kimmelman AC. Metabolic interactions in the tumor microenvironment. Trends Cell Biol. 2017; 27(11): 863–875.

[34] Chang C-H, Qiu J, O'Sullivan D, et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell. 2015; 162(6): 1229–1241.

[35] Mazzoni M, Mauro G, Erreni M, et al. Senescent thyrocytes and thyroid tumor cells induce M2-like macrophage polarization of human monocytes via a PGE2-dependent mechanism. J Exp Clin Cancer Res. 2019; 38(1): 208.

[36] Lacher SB, Dörr J, De Almeida GP, et al. PGE2 limits effector expansion of tumour-infiltrating stem-like CD8+ T cells. Nature. 2024; 629(8011): 417–425.

[37] Xu G, Huang R, Wumaier R, et al. Proteomic profiling of serum extracellular vesicles identifies diagnostic signatures and therapeutic targets in breast cancer. Cancer Res. 2024; 84(19): 3267–3285.

Rights & permissions

2026 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.